The New Hampshire company, co-founded by Kamen, said the findings clear the way for him to continue serving on its board ...
Sequel Med Tech has announced broad national availability of its twist Automated Insulin Delivery (AID) System powered by Tidepool, following clearance by the U.S. Food and Drug Administration in 2024 ...
US-based Sequel Med Tech has introduced its Tidepool-powered twiist automated insulin delivery (AID) system across the country. Following clearance by the US Food and Drug Administration (FDA) in 2024 ...
With nationwide availability now underway, twiist reaches a meaningful milestone in Sequel’s mission to empower the diabetes community with more choice and a more personalized, customizable AID ...
MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and ...
MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (SENS) ...
Sequel Med Tech and Senseonics have announced a collaboration to integrate Sequel’s twiist Automated Insulin Delivery (AID) System with Senseonics’ Eversense 365 one-year Continuous Glucose Monitoring ...
For additional details visit www.twiist.com. About Sequel Med Tech Headquartered in Manchester, N.H., Sequel Med Tech, LLC is developing the next generation of transformative drug-delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results